- Profile
- Personal Information
- Publications
Experts in Cardiology
Prof. Dr. Mohammed Ibrahim Abdel Magued Arunima Sengupta Dr. Naibedya Chattopadhyay David J. Burritt Anthony Emekalam Sunil Baldwa Michael J. Miller Hiroko Beck Vivian M. Abascal David H Adams Susan Zieman Ismayil Ahmet Mingyi Wang ASHEQUL ISLAM Barbara Radziszewska Thomas R. Cimato David M. Zlotnick Ronald Kohanski Gen Suzuki Malcolm McHenry View MoreTim joined the board in October 2013. He has more than 15 years of life sciences business development, alliance management and sales and marketing experience in Europe, Asia and Australia. He is CEO and Managing Director of Cell Therapies Pty Ltd, a leading Asia Pacific provider of manufacturing and distribution of cell-based therapeutics and was President of Asia Pacific for Hospira Inc. (2007 to 2012), having held a variety of senior management roles with Mayne Pharma (2002 to 2007) prior to its acquisition by Hospira. These roles encompassed the development and commercialisation of pharmaceuticals, devices, biologics and cellular therapies. Prior to this, Dr. Oldham was an engagement manager with McKinsey & Co (1997 to 2001). Tim has been chairman of the European Generic Medicines Association Biosimilars and Biotechnology Committee, a Director of the Generic Medicines Industry Association and a member of the Pharmaceutical Industry Strategy Group. He is also a Director of Respiri Ltd (ASX: RSH) and a member of AusBiotech’s Regenerative Medicine Advisory Group. Tim joined the board in October 2013. He has more than 15 years of life sciences business development, alliance management and sales and marketing experience in Europe, Asia and Australia. He is CEO and Managing Director of Cell Therapies Pty Ltd, a leading Asia Pacific provider of manufacturing and distribution of cell-based therapeutics and was President of Asia Pacific for Hospira Inc. (2007 to 2012), having held a variety of senior management roles with Mayne Pharma (2002 to 2007) prior to its acquisition by Hospira. These roles encompassed the development and commercialisation of pharmaceuticals, devices, biologics and cellular therapies. Prior to this, Dr. Oldham was an engagement manager with McKinsey & Co (1997 to 2001). Tim has been chairman of the European Generic Medicines Association Biosimilars and Biotechnology Committee, a Director of the Generic Medicines Industry Association and a member of the Pharmaceutical Industry Strategy Group. He is also a Director of Respiri Ltd (ASX: RSH) and a member of AusBiotech’s Regenerative Medicine Advisory Group.
Pharmaceutical industryÂ